DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Applicant’s amendments, filed 7/02/2026, is acknowledged.
Claims 2-4, 6, 8, 9, and 11-63 are cancelled.
Claims 1, 5, 7, 10, and 64 are currently pending.
Claim 1 is an independent claim.
Claims 7 and 10 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions and/or Species.
Claims 1, 5, and 64 are under examination as drawn to methods of treating CLL comprising administration of a first bispecific molecule comprising a means for binding CD2 and a means for binding CLL-1 and a second bispecific molecule comprising a means for binding a TCR complex or secondary T-cell signaling molecule and a means for binding to CLL.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 7/2/2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner in its entirety.
In view of the amendments and remarks filed on 7/2/2026, the following rejections remain.
Claim Interpretation
The following is a quotation of 35 U.S.C. 112(f):
(f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.
The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph:
An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.
The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked.
As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph:
(A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function;
(B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and
(C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function.
Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function.
Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function.
Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action.
In the instant case instant claim 1 has been amended to recite antigen binding modules 1, 2, 4, and 5, each of which further comprising “a means for binding specifically” to CD2, CLL-1, a human TCR complex, and CLL-1, respectively:
PNG
media_image1.png
370
649
media_image1.png
Greyscale
Applicant states the structures for such means of binding are disclosed in the specification (Remarks pg. 7):
PNG
media_image2.png
266
673
media_image2.png
Greyscale
The instant specification discloses that antigen binding modules are immunoglobulin or non-immunoglobulin based (¶[0035]): “…term "antigen-binding module" or "ABM" as used herein refers to a portion of a MBM that has the ability to bind to an antigen non-covalently, reversibly and specifically. An ABM can be immunoglobulin- or non-immunoglobulin-based”. The instant specification further discloses examples of non-antibody structures that can be binders, such as DARPins, avidity multimers, knottins (¶[0134]), and affilins (¶[0568]-[0569]).
Therefore, the instant claims are interpreted to encompass not only the antibody structures disclosed in the instant specification and mentioned in the Remarks filed 7/02/2026, but also non-immunoglobulin structures, including organic molecule, peptides, nucleic acids, and any structure that can be a means for binding to one of the recited targets.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 1, 5, and 64 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventors, at the time the application was filed, had possession of the claimed invention. This new grounds of rejection is necessitated by Applicant’s amendments.
Claims 1, 5, and 64 encompass methods of treating AML comprising administration of a first bispecific molecule comprising a first AMB comprising a means for binding CD2 and a second AMB comprising a means for binding CLL-1 and a second bispecific molecule comprising a fourth AMB comprising a means for binding a TCR complex (claims 1 and 5) or CD3 (claim 64) and a fifth ABM comprising a means for binding CLL-1.
However, the specification fails to provide adequate written description support for a genus of antibody heavy chain constant regions with no recited structure having the desired functional properties required to practice the claimed functions of “means for binding” of each of the recited antigens.
The claims are not supported by a description that satisfies 35 U.S.C. § 112(a) or 35 U.S.C. § 112, first paragraph. "[T]he test for sufficiency [of the written description] is whether the disclosure of the application relied upon reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date." Ariad Phanns., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en bane).
A "sufficient description of a genus ... requires the disclosure of either a representative number of species falling within the scope of the genus or structural features common to the members of the genus so that one of skill in the art can 'visualize or recognize' the members of the genus." Id. at 1350. "[A]n adequate written description requires a precise definition, such as by structure, formula, chemical name, physical properties, or other properties, of species falling within the genus sufficient to distinguish the genus from other materials." Id.
"[F]unctional claim language can meet the written description requirement when the art has established a correlation between structure and function." Id. "But merely drawing a fence around the outer limits of a purported genus is not an adequate substitute for describing a variety of materials constituting the genus and showing that one has invented a genus and not just a species." Id.
"A sufficient description of a genus ... requires the disclosure of either a representative number of species falling within the scope of the genus or structural features common to the members of the genus so that one of skill in the art can "visualize or recognize" the members of the genus" (AbbVie, 759 F.3d at 1297, reiterating Eli Lilly, 119 F.3d at 1568-69) (emphasis added).
The specification discloses that antigen binding modules can be both immunoglobulin structures (¶[0111]-[0133]) and non-immunoglobulin structures (¶[0134]-[0140]). Non-immunoglobulin structures include (¶[0134]): “…the ABMs of a MBM are derived from nonantibody scaffold proteins (including, but not limited to, designed ankyrin repeat proteins (DARPins), Avimers (short for avidity multimers), Anticalin/Lipocalins, Centyrins, Kunitz domains, Adnexins, Affilins, Affitins (also known as Nonfitins), Knottins, Pronectins, Versabodies, Duocalins, and Fynomers), ligands, receptors, cytokines or chemokines.” The specification discloses examples of such binders such as a CD3 binding Affilin (¶[0568]-[0569]).
With respect to representative number of species, see AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc. (Fed. Cir. 2014). Also, see MPEP 2163 Il(A)(3)(a))(ii):
A representative number of species means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See Abb Vie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014) (Claims directed to a functionally defined genus of antibodies were not supported by a disclosure that "only describe[d] one type of structurally similar antibodies" that "are not representative of the full variety or scope of the genus.").
Satisfactory disclosure of a "representative number" depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features possessed by the members of the genus in view of the species disclosed. For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus. See, e.g., Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. Instead, the disclosure must adequately reflect the structural diversity of the claimed genus, either through the disclosure of sufficient species that are "representative of the full variety or scope of the genus," or by the establishment of "a reasonable structure-function correlation." Such correlations may be established "by the inventor as described in the specification," or they may be "known in the art at the time of the filing date." See AbbVie, 759 F.3d at 1300-01, 111 USPQ2d 1780, 1790-91 (Fed. Cir. 2014) (Holding that claims to all human antibodies that bind IL-12 with a particular binding affinity rate constant (i.e., koff) were not adequately supported by a specification describing only a single type of human antibody having the claimed features because the disclosed antibody was not representative of other types of antibodies in the claimed genus, as demonstrated by the fact that other disclosed antibodies had different types of heavy and light chains, and shared only a 50% sequence similarity in their variable regions with the disclosed antibodies.).
The claims are directed to methods of treating AML comprising administration of a first bispecific molecule comprising a first AMB comprising a means for binding CD2 and a second ABM comprising a means for binding CLL-1 and a second bispecific molecule comprising a fourth ABM comprising a means for binding a TCR complex (claims 1 and 5) or CD3 (claim 64) and a fifth ABM comprising a means for binding CLL-1, however each of the ABMs recited in the claims can comprise not only antibody structures, but non-immunoglobulin structures such as an affilin. However, the instant specification only discloses a limited number of both antibody and non-antibody structures with the recited functions (disclosed, for example, in Tables 11, 13, and 14-24) that does not adequately represent the broadly claimed structures that comprise the ABMs.
Moreover, there is insufficient written description of the required kind of structure-identifying information about the corresponding makeup of the claimed antigen binding modules to demonstrate possession. Also, see Amgen Inc. v. Sanofi, Aventisub LLC, No. 2017-1480 (Fed. Cir. 2017). The Court reiterated that adequate written description must “contain enough information about the actual makeup of the claimed products . . . .” The Court simultaneously suggested that the “newly characterized antigen” test “flouts” section 112 because it “allows patentees to claim antibodies by describing something that is not the invention, i.e., the antigen.” The Court concluded that for written description of an antibody to be adequate when presented with “functional” terminology, there must be an established correlation in the art between structure and function.
Given the broadly claimed class of antigen binding modules, and in the absence of sufficient disclosure of relevant identifying characteristics for the broadly claimed class of antigen binding molecules that bind to a ligand, the patentee must establish “a reasonable structure-function correlation” either within the specification or by reference to the knowledge of one skilled in the art with functional claims. AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc. (Fed. Cir. 2014), MPEP 2163.
The specification at best describes plan for making ABMs that have the recited functions of “means for binding specifically to human CD2”, “means for binding specifically to human CLL-1”, or “means for binding specifically to human TCR complex”, and then identifying those that satisfy the claim limitations, but a mere “wish or plan” for obtaining claimed invention is not sufficient. Centocor Ortho Biotech Inc. v. Abbott Laboratories, 97 USPQ2d 1870 (Fed. Cir. 2011).
The specification discloses only a limited number of ABMs within the claimed scope. First, regarding immunoglobulin-based ABMs, it is unlikely that antibodies or fragments thereof as defined by the claims which may contain less than the full complement of CDRs from the alpha and beta chain variable regions of the antibody structures disclosed in the specification fused to framework sequences have the required binding function. Regarding non-immunoglobulin-based ABMs, the specification provides no guidance on how to generate such structures that can be used in the claimed methods of treating AML, such as other affilin structures. The specification provides no direction or guidance regarding how to produce antigen binding constructs with the functions of “means for binding specifically to human CD2”, “means for binding specifically to human CLL-1”, or “means for binding specifically to human TCR complex” as broadly defined by the claims.
Possession is not be shown by merely describing how to obtain possession of members of the claimed genus or how to identify their common structural features. See University of Rochester, 358 F.3d at 927, 69 USPQ2d at 1895. Sufficient description to show possession of such a genus may be achieved by means of a recitation of a representative number of anti-TMPRSS6 antibodies or antigen binding fragments thereof falling within the scope of the genus or of a recitation of structural features common to members of the genus, which features constitute a substantial portion of the genus. See Eli Lilly, 119F.3d at 1568, 43 USPQ2d at 1406.
Claims 1, 5, and 64 do not meet the requirements of 35 U.S.C. 112(a) for written description.
Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the written description inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.). Consequently, Applicant was not in possession of the instant claimed invention. See University of California v. Eli Lilly and Co. 43 USPQ2d 1398.
Applicant’s arguments, filed 7/2/2026, are moot in light of this new rejection.
Applicant is invited to point to clear support or specific examples of the claimed invention in the specification as-filed.
To overcome this rejection, it is recommended to amend the claims to recite specific structures that have the recited binding functions. For example, specific antibody structures as defined by their CDR amino acid sequences, as well as the epitope the antibody structure binds to.
Claims 1, 5, and 64 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention. This new grounds of rejection is necessitated by Applicant’s amendments.
The claims are rejected for the same reasons discussed in the Office Action mailed on 1/06/2026. Briefly, the instant specification does not enable one to make and use the claimed method of treating AML comprising administration of a first bispecific molecule comprising a first AMB comprising a means for binding CD2 and a second AMB comprising a means for binding CLL-1 and a second bispecific molecule comprising a fourth AMB comprising a means for binding a TCR complex (claims 1 and 5) or CD3 (claim 64) and a fifth ABM comprising a means for binding CLL-1. In light of the specification (see 112(f) interpretation supra), each of the “means for binding” encompasses a broad genus of any structure that has the recited functions, including immunoglobulin and non-immunoglobulin structures.
Applicant’s arguments, filed 7/02/2026, have been fully considered, but have been found to be not convincing.
Applicant argues that the amended claims to recite a means-plus-function format, however the claims are still interpreted to encompass broad genera of binding modules with little to no recited structure (supra).
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 5, and 64 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 recites methods of treating AML comprising administration of a bispecific binding molecule comprising an ABM1 and ABM2, as well as a bispecific binding molecule comprising an ABM4 and ABM5. The claim is currently indefinite because it is unclear whether or not the claimed methods also comprise an ABM3 or not, as a fourth and fifth antigen binding module imply that a third is present. Claims 5 and 64 depend on claim 1 and do not resolve this issue and are also rejected as indefinite.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1, 5, and 64 are rejected under 35 U.S.C. 103 as being unpatentable over Leong et al. (Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365) in view of Ebersbach et al. (WO2017125897). This new grounds of rejection is necessitated by Applicant’s amendments.
Leong et al. teaches anti-CD3/anti-CLL-1 bispecific antibodies were able to target and kill AML cell lines (Results): “…using a bispecific antibody targeting CLL-1 and CD3e to redirect the human immune system is effective against a variety of AML subtypes and clinical AML samples…” Leong et al. teaches that these bispecific antibodies can be used to treat AML in a subject (Discussion): “…a full-length humanized-IgG TDB-targeting human CLL-1 and human CD3ε is a feasible approach to eradicate CLL-11 leukemic cells. The superior pharmacokinetic properties of an IgG antibody and low liability for off-target destruction of HSCs make this attractive as a potential targeted therapy for AML”
Leong et al. does not teach a method of treating AML comprising administration of a bispecific anti-CLL-1/CD3 antibody (i.e., “an antigen-binding module 4 (ABM4) comprising means for binding specifically to human CD3” and “an antigen-binding module 5 (ABM5) comprising means for binding specifically to human CLL-1”) and a bispecific anti-CLL-1/CD2 antibody (i.e., “an antigen-binding module 1 (ABM1) comprising means for binding specifically to human CD2” and “an antigen-binding module 2 (ABM2) comprising means for binding specifically to human CLL-1”; the limitations of instant claims 1, 5, and 64).
Ebersbach et al., in the same field of endeavor, teaches multispecific molecule comprising an anti-CLL-1 binding antibody arm (claim 1-4), and an anti-CD2 binding antibody arm (claims 13 and 16-18). Ebersbach et al. teaches methods of treating cancer comprising administration of the multispecific molecule (claim 69), including AML (claim 72).
It would have been obvious to one with ordinary skill in the art, before the effective filing date of the instant application, to have combined the method of treatment of AML taught and suggests by Leong et al. with the methods of treating AML taught by Ebersbach et al. with a reasonable expectation of success, as both are methods of treatment comprising administration of a bispecific antibody that one with ordinary skill would be able to combine. One would have been motivated to make this change to develop a more effective treatment of AML.
Additionally, it is prima facie obvious to combine two compositions each of which is taught by prior art to be useful for same purpose in order to form third composition that is to be used for very same purpose; the idea of combining them flows logically from their having been individually taught in prior art. In re Kerkhoven, 205 USPQ 1069, CCPA 1980. See MPEP 2144.06. In re Couvaras, 70 F.4th 1374, 1378-79, 2023 USPQ2d 697 (Fed. Cir. 2023) (That the two claimed types of active agents, GABA-a agonists and ARBs, were known to be useful for the same purpose—alleviating hypertension—alone can serve as a motivation to combine).
The combined references teach a method of treating AML comprising administration of a first bispecific antibody that is anti-CLL/anti-CD3 (i.e., “an antigen-binding module 4 (ABM4) comprising means for binding specifically to human CD3” and “an antigen-binding module 5 (ABM5) comprising means for binding specifically to human CLL-1”) and an anti-CLL-1/CD2 bispecific antibody (i.e., “an antigen-binding module 1 (ABM1) comprising means for binding specifically to human CD2” and “an antigen-binding module 2 (ABM2) comprising means for binding specifically to human CLL-1”), meeting the limitations of instant claims 1, 5, and 64.
Applicant’s arguments, filed 7/02/2026, have been considered moot in light of this new rejection.
Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1, 5, and 64 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 12,037,378 (Pat ‘378) in view of Ebersbach et al. (WO2017125897, supra) and Leong et al. (Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365, supra). Although the claims at issue are not identical, they are not patentably distinct from each other. This new grounds of rejection is necessitated by applicant’s amendments.
Pat ‘378 claims CD2 binding molecules comprising a variant CD58 domain (i.e., “a means for binding specifically to CD2”; Pat ‘378 claim 1), as well as bispecific binding molecules comprising the CD2 binding molecule (claim 2). Pat ‘378 additionally claims methods of treating cancer comprising administration of the binding agent (claim 7), as well as AML (claim 8).
Pat ‘378 does not claim methods of treating AML comprising bispecific molecules comprising the CD2 binding domain and a means for binding to CLL-1, as well as an anti-CD3/anti-CLL-1 bispecific binding molecule.
Ebersbach et al., in the same field of endeavor, teaches multispecific molecule comprising an anti-CLL-1 binding antibody arm (claim 1-4), and an anti-CD2 binding antibody arm (claims 13 and 16-18). Ebersbach et al. teaches methods of treating cancer comprising administration of the multispecific molecule (claim 69), including AML (claim 72).
Leong et al., in the same field of endeavor, teaches anti-CD3/anti-CLL-1 bispecific antibodies were able to target and kill AML cell lines (Results): “…using a bispecific antibody targeting CLL-1 and CD3e to redirect the human immune system is effective against a variety of AML subtypes and clinical AML samples…” Leong et al. teaches that these bispecific antibodies can be used to treat AML in a subject (Discussion): “…a full-length humanized-IgG TDB-targeting human CLL-1 and human CD3ε is a feasible approach to eradicate CLL-11 leukemic cells. The superior pharmacokinetic properties of an IgG antibody and low liability for off-target destruction of HSCs make this attractive as a potential targeted therapy for AML”.
It would have been obvious to one with ordinary skill in the art to have modified the invention claimed by Pat ‘378 in view of Ebersbach et al. and Leong et al. to develop a method of treating AML comprising a bispecific anti-CD2/anti-CLL-1 binding molecule and an anti-CD3/anti-CLL-1 binding molecule (i.e., the limitations of instant claims 1, 5, and 64) with a reasonable expectation of success, as all of the references teach methods of treating AML that one with ordinary skill in the art would be able to combine, for example by incorporating the anti-CLL-1 binding arm taught by Ebersbach et al. into the bispecific binding molecule claimed by Pat’378, and then administering this bispecific molecule with the bispecific anti-CD3/anti-CLL-1. One would have been motivated to make this change for the purposes of developing a more effective method of treating AML.
Additionally, it is prima facie obvious to combine two compositions each of which is taught by prior art to be useful for same purpose in order to form third composition that is to be used for very same purpose; the idea of combining them flows logically from their having been individually taught in prior art. In re Kerkhoven, 205 USPQ 1069, CCPA 1980. See MPEP 2144.06. In re Couvaras, 70 F.4th 1374, 1378-79, 2023 USPQ2d 697 (Fed. Cir. 2023) (That the two claimed types of active agents, GABA-a agonists and ARBs, were known to be useful for the same purpose—alleviating hypertension—alone can serve as a motivation to combine).
Applicant’s arguments, filed 7/02/2026, have been considered moot in light of this new rejection.
Therefore, the instantly claimed invention is a prima facie obvious variant of the invention claimed by Pat ‘378 in view of Ebersbach et al. and Leong et al., especially in absence of evidence to the contrary.
Claims 1, 5, and 64 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, 22, 23, 28, 34, 35, 40, 41, 44, 45, and 47-50 of copending Application No. 17/311,315 (App ‘315) in view of Ebersbach et al. (supra) and Leong et al. (supra). Although the claims at issue are not identical, they are not patentably distinct from each other. This new grounds of rejection is necessitated by applicant’s amendments.
App ‘315 claims bispecific binders comprising anti-CD3 binding arms (i.e., “a means for binding CD3”) as well as an anti-TAA binding arm (claim 28), wherein the TAA is CLL-1 (claim 40). App ‘315 additionally claims binders comprising an anti-CD2 binding arm and an anti-TAA binding arm (claim 34).
The instantly claimed invention is a prima facie obvious variant of the invention claimed by App ‘315 in view of Ebersbach et al. (supra) and Leong et al. (supra) for the same reasons discussed for Pat ‘378 supra. This is a provisional double patenting rejection.
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEC JON PETERS whose telephone number is (703)756-5794. The examiner can normally be reached Monday-Friday 8:30am - 6:00pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Misook Yu can be reached at (571) 272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ALEC JON PETERS/Examiner, Art Unit 1641
/MISOOK YU/Supervisory Patent Examiner, Art Unit 1641